Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

被引：0
|
作者：
Yao, B. [1 ]
Yang, L. F. [1 ]
Ran, T. [1 ]
Deng, S. [1 ]
Xu, Q. [1 ]
机构：
[1] Tongren City Peoples Hosp, Tongren, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
osimertinib; aumolertinib; safety intolerant;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-63
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [1] Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S468 - S468
  • [2] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [3] The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study
    Sun, L.
    Huang, X.
    Zhong, M.
    Huang, J.
    Cai, Y.
    Huang, J.
    Liu, H.
    Qin, H.
    Li, J.
    Zhong, B.
    Zuo, H.
    Zhang, G.
    Yan, J.
    Chen, Z.
    Chen, Y.
    He, L.
    Xiong, Y.
    Xu, M.
    Pan, L.
    Xiong, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S640 - S641
  • [4] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
  • [5] Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib
    Chen, E.
    Lou, J.
    Hu, X.
    Wen, S.
    Zhu, X.
    Jiang, Z.
    Li, Q.
    Le, L.
    Sheng, Y.
    Wu, S.
    Zou, J.
    Lu, Y.
    Chen, J.
    Xu, H.
    Zhang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S647 - S648
  • [6] Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
    Ji, Jingran
    Aredo, Jacqueline, V
    Piper-Vallillo, Andrew
    Huppert, Laura
    Rotow, Julia K.
    Husain, Hatim
    Stewart, Susan
    Cobb, Rosemary
    Wakelee, Heather A.
    Blakely, Collin M.
    Wong, Melisa L.
    Gubens, Matthew A.
    Madani, Mohammad H.
    Digumarthy, Subba R.
    Mccoach, Caroline
    Piotrowska, Zofia
    Neal, Joel W.
    Riess, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):
  • [7] Comparative study on safety after primary and secondary treatment in EGFR positive NSCLC administered Osimertinib
    Umehara, Kengo
    Gto, Keisuke
    Okayama, Yuki
    Noomote, Shiori
    Toda, Takayuki
    Okazaki, Yasuka
    Wakamoto, Azusa
    Hatsuyama, Tae
    Honjo, Osamu
    Sato, Hideki
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
    Pizzutilo, E. G.
    Cerea, G.
    Oresti, S.
    Agostara, A. G.
    Signorelli, D.
    Stabile, S.
    Lauricella, C.
    Brambilla, M.
    Mazzeo, L.
    Giusti, R.
    Montrone, M.
    Russano, M.
    Bennati, C.
    Russo, A.
    Viscardi, G.
    Roca, E.
    Gelibter, A. J.
    Cortinovis, D. L.
    Bianchi, A. Sartore
    Siena, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1009 - S1009
  • [9] Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
    Pizzutilo, E. G.
    Agostara, A. G.
    Oresti, S.
    Signorelli, D.
    Giannetta, L. G.
    Stabile, S.
    Lauricella, C.
    Amatu, A.
    Brambilla, M.
    Lo Russo, G.
    Proto, C.
    Mazzeo, L.
    Beninato, T.
    Siringo, M.
    Giusti, R.
    Filetti, M.
    Genova, C.
    Barletta, G.
    Russano, M.
    Di Fazio, G. R.
    Tosoni, E.
    Metro, G.
    Pilotto, S.
    Carta, A.
    Mazzoni, F.
    Roca, E.
    Gelibter, A. J.
    Gori, S.
    Berardi, R.
    Cerea, G.
    Sartore-Bianchi, A.
    Siena, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S418 - S419
  • [10] Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
    Fang, W. F.
    Bu, Q.
    Wang, Q. M.
    Zhao, W. H.
    Wang, L. P.
    Dong, X. R.
    Chen, P. F.
    Wen, Z. B.
    Jia, J.
    Jiang, G. M.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S333 - S334
12345